Research
Sell
A Sell rating means lf0 research identifies a meaningful gap between a companys current valuation and its underlying fundamentals, typically driven by decelerating growth, margin pressure, balance-sheet risk, or a competitive position eroding faster than the market has priced in. Sell-rated companies carry a risk/reward skew that favors caution over the timeframe of the analysis.
The Scorecard: 1 Month Update: BMNR Sell — Incorrect so far
Revisiting our Sell call on BMNR: entry $17.74, latest $22.83, +28.7%.
The Scorecard: 2 Month Update: CAR Sell — Correct so far
Revisiting our Sell call on CAR: entry $186.28, latest $146.61, -21.3%.
The Scorecard: 1 Month Update: MARA Sell — Correct so far
Revisiting our Sell call on MARA: entry $11.67, latest $8.96, -23.2%.
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just…
The Scorecard: 1 Month Update: MYRG Sell — Correct so far
Revisiting our Sell call on MYRG: entry $391.51, latest $340.78, -13.0%.
The Scorecard: 2 Month Update: SOUN Sell — Incorrect so far
Revisiting our Sell call on SOUN: entry $7.33, latest $7.43, +1.4%.
The Scorecard: 1 Month Update: ONTO Sell — Incorrect so far
Revisiting our Sell call on ONTO: entry $319.32, latest $331.71, +3.9%.
The Scorecard: 1 Month Update: AMBA Sell — Incorrect so far
Revisiting our Sell call on AMBA: entry $72.90, latest $82.04, +12.5%.
The Scorecard: 1 Month Update: HUT Sell — Correct so far
Revisiting our Sell call on HUT: entry $98.33, latest $85.44, -13.1%.
The Scorecard: 2 Month Update: SKYH Sell — Incorrect so far
Revisiting our Sell call on SKYH: entry $9.37, latest $11.20, +19.5%.
Most Popular Research